1. Department of Immunology, Weizmann Institute of Science, Rehovot, Israel;
2. German Cancer Research Center (DKFZ), Heidelberg, Germany;
3. Division of Molecular Oncology and
4. Laboratory of Clinical Oncology, Institute for Cancer Research and Treatment, University of Turin Medical School, Candiolo, Italy;
5. Ecole Polytechnique Fédérale de Lausanne (EPFL), ISREC – Swiss Institute for Experimental Cancer Research, School of Life Science, Epalinges, Switzerland;
6. Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany; and
7. Pfizer Global Research and Development, La Jolla, CA